Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(tested or 100% immunogen sequence identity)
Western blot (1:1000 - 1:5000)
ELISA (1:10000 - 1:100000)
ADRB3 antibody was raised against a 19 amino acid peptide sequence mapping at the C-terminus of the mouse B3AR (2) was used to generate anti- B3AR. The peptide was coupled with KLH (carrier protein).
The 20 AA mouse B3AR immunogenic peptide sequence is 85% homologous with rat B3AR (17/20). It has no significant homology with the human B3AR. Anti-B3AR11 antibodies are not likely to cross-react with mouse/rat B3AR. Actual cross-reactivity of antibodies in all species is not established. Control peptides, because of their low MW (<3kD), are not suitable for Western. It should be used for ELISA or antibody blocking to confirm antibody specificity.
Suitable for use in ELISA, Western Blot. Western Blot: 1:1000-1:5000 for neat serum and 1-10 ug/ml for affinity pure using ECL. ELISA: 1:10000-1:100000 using 50-100 ng B3AR control peptide/well.
PBS, 0.05% Sodium Azide
Short term: 4°C. Long term: Store at -20°C. Avoid freeze-thaw cycles.
The Beta-3 Adrenoceptor (ADRB3) is an Adrenergic Receptor that stimulates lipolysis and increases fatty acids in the blood. Stimulation of the beta-3 adrenoceptor leads to lipolysis in white adipocytes and nonshivering thermogenesis in brown fat. The beta-3 adrenoceptor has also been suggested to affect the physiological control of cardiac and vascular contractility; beta-3 adrenoceptor stimulation decreases cardiac contractility through activation of a nitric oxide synthase pathway.